10 Mar Scientific Summits conference — Ostend, 20 & 21 May 2022
We have the honour to invite you to the first Scientific Summits conference of this year, on Friday 20 & Saturday 21 May 2022 in the iconic Thermae Palace Hotel, located in the majestic city of Ostend.
LIVE PRESENCE & ONLINE STREAM
We will welcome as many guests as possible, live in Ostend, obviously taking into account the corona measures applicable at that moment.
To give everyone the opportunity to attend the conference, all sessions will also be recorded and broadcasted online with the help of a high profile technical partner, enabling speakers, attendees & experts to discuss in a virtual ZOOM conference room.
TOP SPEAKERS, TOP CONTENT
As usual, we are proud to once again offer a varied program, with top key opinion leaders & international experts, offering insights into important novelties in the field of urothelial, prostate and kidney cancer.
Friday 20 & Saturday 21 May 2022
Hybrid meeting
Thermae Palace Hotel
Koningin Astridlaan 7
8400 Ostend
Belgium
Scientific program
Friday 20 May 2022
12u00 – 13u00
LUNCH
13u00 – 13u30
Part 1 — NMIBC
Panel: Dr. Simone Albisinni – Hôpital Erasme, Brussels / Dr. Koen Slabbaert – RZ Tienen / Prof. Dr. Christof Vulsteke – AZ Maria Middelares Gent
BCG shortage: practical solutions
Speakers: Prof. Dr. Paolo Gontero – Molinette Hospital, Torino, Italy
13u35 – 14u35
Part 2 — MIBC
Panel: Prof. Dr. Brieuc Sautois – CHU Liège / Dr. Frederiek D’Hondt – OLV Ziekenhuis Aalst / Prof. Dr. Steven Joniau – UZ Leuven
13u35 – 14u05
What exactly are CTLA / PD-1 / PD-L1 / antibody drug conjugates? A guide for dummies.
Speaker: Prof. Dr. Christof Vulsteke – AZ Maria Middelares Gent
14u05 – 14u35
Reality in clinical trials
Speaker: Prof. Dr. Tom Powles – Barts Cancer Centre, London, UK
14u40 – 16u20
Part 3 — Renal cell carcinoma
Panel: Dr. Charlien Berghen – UZ Leuven / Dr. Peter Dekuyper – AZ Maria Middelares Gent / Prof. Dr. Christof Vulsteke – AZ Maria Middelares Gent / Dr. Laurent Fossion – CHU-Brugmann, Brussels
14u40 – 15u00
Stereotactic body radiotherapy and the immune system: a guide for dummies
Speaker: Dr. Nora Sundahl – UZ Gent
15u00 – 16u00
Case discussion SBRT in low-volume mRCC
- Low-volume metastatic RCC: prime time for metastasis-directed therapy
Case presentation: Dr. Charlien Berghen – UZ Leuven - Stereotactic body radiotherapy
Speaker: Prof. Dr. Shankar Siva – Icon Cancer Centre Richmond, Australia - Debate: adjuvant immune therapy is needed after metastasis-directed therapy
PRO: Prof. Dr. Maarten Albersen – UZ Leuven
CON: Prof. Dr. Shankar Siva – Icon Cancer Centre Richmond, Australia - Discussion & case conclusion
16u00 – 16u20
Update on adjuvant trials in RCC
Speaker: Prof. Dr. Axel Bex – Antoni van Leeuwenhoek, Amsterdam, The Netherlands
16u20 – 16u50
Coffee break
16u50 – 17u30
Part 4 — Ethics and Economy
Panel: Prof. Dr. Filip Ameye – AZ Maria Middelares Gent / Prof. Dr. Gert De Meerleer – UZ Leuven / Dr. Lieven Goeman – AZ Delta
The “Vandenbroucke” note – impact on oncological practice: an open panel discussion
Speaker: Dr. Thomas Gevaert – AZ Klina
17u30 – 18u15
Part 5 — Mini symposium: BMS (Nivolumab)
Panel: Prof. Dr. Steven Joniau – UZ Leuven / Prof. Dr. Brieuc Sautois – CHU Liège / Prof. Dr. Patrick Pauwels – UZA
Novel immunotherapy option in muscle invasive urothelial carcinoma: multidisciplinary panel discussion
18u15 – 19u00
Network drink
19u00
CONGRESS DINNER
Saturday 21 May 2022
09u45 – 10u55
Part 6 — Prostate
09u45 – 10u10
Retzius-sparing approach: can we make final conclusions on this novel technique?
Speaker: Dr. Antonio Galfano – ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Panel: Prof. Dr. Tobias Maurer – Martini-Klinik, Hamburg, Germany / Dr. Thomas Adams – GZA Ziekenhuis Antwerpen / Dr. Charles Van Praet – UZ Gent
10u15 – 10u55
Salvage resection of local recurrence
- Salvage vesiculectomy / salvage radio-guided surgery
Speaker: Prof. Dr. Tobias Maurer – Martini-Klinik, Hamburg, Germany - Salvage HDR-brachytherapy
Speaker: Dr. Carl Salembier – Europe Hospitals, Brussels - Discussion
Panel: Prof. Dr. Alberto Bossi – IGR, Paris, France / Prof. Dr. Steven Joniau – UZ Leuven / Prof. Dr. David Dearnaley – The Institute of Cancer Research, UK
10u55 – 11u25
Coffee break
11u25 – 13u10
Part 6 — Prostate
(continued)
11u25 – 12u15
Looking beyond the STAMPEDE trial: treatment intensification is the new standard in high-risk Pca
- Combination systemic treatment
Speaker: Prof. Dr. Gerhardt Attard – UCL Cancer Institute, UK - Treatment of the primary tumor is key
- Radiotherapy
Speaker: Prof. Dr. David Dearnaley – Institute of Cancer Research, UK - Radical prostatectomy
Speaker: Prof. Dr. Steven Joniau – UZ Leuven
- Radiotherapy
- Discussion
Panel: Prof. Dr. Alberto Bossi – IGR, Paris, France / Dr. Carl Salembier – Europe Hospitals, Brussels / Prof. Dr. Brieuc Sautois – CHU Liège / Dr. Peter Schatteman – OLV Ziekenhuis Aalst
12u20 – 12u45
Metastatic prostate cancer: Should we all change to triple therapy or not: a critical appraisal
Speaker: Prof. Dr. Karim Fizazi – Gustave Roussy, France
Panel: Dr. Simon Van Wambeke – ZNA Jan Palfijn / Dr. Charles Van Praet – UZ Gent / Prof. Dr. Brieuc Sautois – CHU Liège
12u50 – 13u10
Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?
Speaker: Dr. Simon Van Wambeke – ZNA Jan Palfijn
Panel: Prof. Dr. Christof Vulsteke – AZ Maria Middelares Gent / Prof. Dr. Gert De Meerleer – UZ Leuven / Dr. Peter Schatteman – OLV Ziekenhuis Aalst / Prof. Dr. Brieuc Sautois – CHU Liège